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Exhaled nitric oxide; relationship to 
clinicophysiological markers of asthma severity 
M. K. AL-ALI, C. EAMES, AND P. H. HOWARTH 
University Medicine, Southampton General Hospital, Southampton, U.K. 
Bronchial asthma is an airway disorder associated with bronchial hyperresponsiveness, variable airflow obstruction 
and elevated levels of nitric oxide (NO) in exhaled air. The variables all reflect, in part, the underlying airway 
inflammation in this disease. To understand their interrelationships we have investigated the relationship between 
exhaled NO levels and clinicophysiological markers of asthma severity. 
Twenty-six steroid naive atopic asthmatics participated in the analysis. All were given diary cards and were asked 
to record their peak expiratory flow (PEF) rates twice daily together with their asthma symptom scores and P-agonist 
use. Diary cards were collected 2 weeks later and measurements of exhaled NO levels, FEV, and histamine bronchial 
hyperreactivity (PC,, histamine) were undertaken. 
Exhaled NO levels were significantly higher in our study population than in normal control subjects and 
correlated negatively with PC,, histamine (Y= - 0.51; P=O.OOS) and positively with PEF diurnal variability (r=0.58; 
P=O.O02), but not with symptom scores, P-agonist use or FEV, (“A). 
We conclude that a significant relationship exists between exhaled NO levels and the two characteristic features 
and markers of asthma severity, namely bronchial hyperreactivity and PEF diurnal variability. The lack of 
correlation between symptom score and P-agonist use, or FEV, (%) predicted and exhaled NO suggests that these 
measures are reflective of differing aspects of asthma. 
RESPIR. MED. (1998) 92, 908-913 
Introduction 
Bronchial asthma is an inflammatory disease of the airways 
associated with bronchial hyperresponsiveness (BHR) and 
variable airflow obstruction (1,2). A number of inflam- 
matory cells have been implicated in the pathogenesis of 
this disease through their ability to synthesize and release 
various mediators and pro-inflammatory cytokines (24). 
Nitric oxide (NO) is a free radical gas produced 
endogenously from the amino acid L-arginine through the 
action of the enzyme nitric oxide synthase (NOS) (5), of 
which at least three isoforms are known, two being consti- 
tutive and one inducible (6-8). The inducible isoform 
(iNOS) is upregulated by pro-inflammatory cytokines (9) 
and there is evidence of increased expression of iNOS in 
asthmatic airways (10). This increased epithelial expression 
of iNOS is likely to be a significant factor underlying the 
increased levels of exhaled NO seen in asthmatics (11-13). 
Exhaled NO levels are increased in allergen-induced late 
asthmatic reactions (14) while neither early reactions nor 
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acute changes in airway calibre, induced by methacholine 
or salbutamol, are associated with significant changes in 
exhaled NO levels (15). Furthermore, inhaled steroids 
which are known to reduce airway inflammation (16) and 
BHR (17,18), are associated with lower levels of exhaled 
NO in asthmatics (15,19). All these observations suggest 
that exhaled NO levels in asthmatics are a reflection of 
the underlying airway inflammation and thus potentially 
provide a valuable clinical measure. There are, however, no 
detailed studies investigating the relationship between this 
marker and other markers of disease activity in asthma. 
Thus to explore the relationship between exhaled NO 
levels and clinicophysiological markers of asthma severity, 
as reflected by symptom scores, P-agonist use, lung function 
and BHR, we have made these measurements in a group 
of steroid-naive asthmatics only receiving treatment with 
P-agonists. 
Materials and Methods 
PATIENTS 
Twenty-six asthmatic patients were studied (15 males and 
11 females) with a mean age of 27 years (range 1847 years) 
(Table 1). All were non-smokers, had a clinical diagnosis of 
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TABLE 1. Patient characteristics, clinical indices of asthma severity, PC,, histamine and exhaled NO levels 
Patient Age 
no. (years) 
1 26 
2 21 
3 31 
4 22 
5 30 
6 18 
7 32 
8 37 
9 26 
10 20 
11 35 
12 26 
13 21 
14 28 
15 39 
16 34 
17 23 
18 19 
19 32 
20 19 
21 25 
22 18 
23 35 
24 19 
25 47 
26 27 
Mean 27.3 
SEM 1.5 
Sex 
M 
F 
M 
M 
M 
M 
F 
M 
M 
F 
M 
M 
F 
F 
M 
M 
M 
F 
M 
M 
F 
M 
F 
F 
F 
F 
FEV, PEF Sympton P-Agonist PC,& NOT 
(O/O predicted) variability* scoret useI (mg ml-’ (wb) 
88 5.9 15 40 1.82 13 
90 I.5 16 44 4.70 12 
107 11.7 16 71 2.23 29 
88 10.4 6 8 2.72 15 
69 17.7 5 6 0.12 31 
94 11.5 20 38 8.77 18 
93 20 10 26 0.23 32 
113 8 2 2 0.38 32 
92 10.7 16 32 0.62 31 
93 8 18 37 0.47 23 
91 8.9 29 102 0.37 39 
86 7.4 14 21 1.7 13 
106 6.4 6 15 1.17 8 
85 13.5 8 17 0.56 34 
71 15.7 15 41 0.16 21 
100 10.1 12 16 0.68 7 
84 4.3 4 6 0.19 16 
64 6.4 13 51 0.06 16 
68 11.2 14 28 0.71 18 
87 6.1 4 4 3.33 13 
92 8.4 3 5 0.42 12 
102 8.4 5 6 1.16 9 
65 8.1 13 80 0.40 13 
77 23.5 13 41 0.04 28 
99 9 10 20 1.53 16 
89 7 16 72 1.81 7 
88 10.2 11.7 32.1 0.73 16.0 
2.5 0.9 1.2 5.1 0.04-8.77 7-37 
*PEF variability expressed as the amplitude as a percentage of the mean over 7 days. 
tTota1 symptom scores over 7 days. 
SNumber of puffs of P-agonist used over 7 days. 
§Cumulative concentration of histamine (mg) that induces a 20% fall in FEV, expressed as the geometric mean (range). 
TExhaled NO levels parts per billion, results expressed as median (range). 
asthma and were atopic as evidenced by positive epi- 
cutaneous skin prick test (>3 mm wheal diameter) to one or 
more of the common inhalant allergens (Dermatophugoides 
pteronyssinuss, tree pollen, grass pollen, cat fur, dog hair 
and Aspergillus jiimigatus: Bayer Corporation, Pharma- 
ceutical Division, Elkhart, U.S.A). None of these patients 
had received disease modifying therapy, their sole medica- 
tion being p.r.n. short-acting P-agonists as bronchodilators. 
No patient had experienced an upper or lower respiratory 
tract infection or acute exacerbation of their asthma within 
8 weeks prior to the study. The study was approved by the 
Southampton Hospitals and University Ethics Committee 
and all patients gave written informed consent. 
STUDY DESIGN 
Patients with a clinical diagnosis of asthma and prescribed 
P-agonists by their general practitioner were provided with 
peak flow meters and diary cards and asked to keep daily 
records over a 2 week period. Peak expiratory flow rates 
(PEF) were measured twice daily, morning (06:00&09:00 
hours) and evening (18:00-21:00 hours), and at the same 
time symptom scores and ,&agonist usage in the preceding 
day or night were entered in the diary cards. The diary 
cards were collected at the end of this 2 week period and 
at this visit measurements were made of exhaled NO 
levels, lung function and bronchial reactivity by histamine 
inhalation challenge. 
The study was approved by the Southampton Hospital 
and University Joint Ethical Committee, and a written 
informed consent was given by each patient. 
LUNG FUNCTION 
Peak expiratory flow was measured by patients using a 
Wright mini peak flow meter (Wright. Derby, U.K.). Morn- 
ing and evening measurements were made at the same time 
of day with the morning values being recorded prior to any 
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P-agonist use on waking. For each PEF measurement the 
best of three readings was entered in the diary card. Data 
from the 7 days with complete PEF measurements closest 
to the date of the second visit were used for analysis. 
At the second visit, following abstinence from inhaled 
P-agonists for at least 6 h, FEV, was measured using a dry 
spirometer (Vitalograph Ltd, Buckingham, U.K.). The best 
of three measurements was expressed as a percentage of the 
predicted value [FEV, (“!)I and used for the comparative 
analysis. PEF variability was expressed as the diurnal PEF 
variation (amplitude as a percentage of the mean) (20) and 
defined as [(highest PEF-lowest PEF)/(mean value of these 
two)] x 100% over a period of 7 days. 
SYMPTOM SCORES AND P-AGONIST USAGE 
Diary cards were completed every morning and evening by 
entering the symptom scores for the preceding 12 h using a 
four-point scale (0, no symptoms; 1, mild, 2, moderate; 3, 
severe), with a maximum score of 42 for 1 week. At the 
same time /?-agonist usage for the preceding 12 h was 
entered as the number of puffs used. Data collected from 
the same days used for PEF evaluation were used for 
analysis. 
NO MEASUREMENTS 
Exhaled NO levels were measured as a mixed exhaled air 
sample using a chemiluminescent analyser (model 9841A, 
Siemens Plessey, Dorset, U.K.) with a detection threshold 
of 1 part per billion (ppb). The analyser was calibrated daily 
using NO-free air and a certified gas cylinder of 525 ppb of 
NO (MG Gas Products Ltd, Surrey, U.K.). The method 
was described previously (21). Briefly, while quietly seated 
and wearing nose clips, patients who were tidally breathing 
at a normal respiratory rate were asked to take a full 
inspiration and then immediately to exhale through a 
mouthpiece to fill a 500 ml reservoir bag attached to the 
analyser. Once the reservoir bag was filled, the sample was 
continuously analysed until the bag was empty. The peak 
concentration of NO was recorded and the mean of three 
readings was considered for evaluation. 
HISTAMINE BRONCHIAL CHALLENGE 
BHR was assessed in all patients, after they omitted their 
bronchodilator therapy for at least 6 h, using a five-breath 
inhalation technique modified from that of Chai et al. (22). 
Histamine acid phosphate (Sigma, Dorset, U.K.) dissolved 
in 0.9% saline was administered in increasing doubling 
concentrations (0.03 mg ml - i-8.0 mg ml - ‘) from an 
inspiron mini nebulizer (CR Bard International, 
Sunderland, U.K.) following a saline control inhalation as 
described previously (23). PC,, was derived as the cumula- 
tive concentration of histamine (mg) that induced a 20% fall 
from the post-saline FEV, and obtained by linear interpo- 
lation between the last two points of the log (concentration) 
response curve. 
10 20 
Rank of log PCs,, 
FIG. 1. Relationship between PC,, histamine and FEV, 
(% predicted) (r=0.44; P=O.O26). 
STATISTICAL ANALYSIS 
The Mann-Whitney U test was used to compare exhaled 
NO levels in asthmatics and control subjects. Relationships 
were tested using Spearman’s rank correlation coefficient. 
Results were expressed as mean f SEM unless stated 
otherwise. A P value of co.05 was considered as significant. 
Results 
Results of diary card recordings, lung function and BHR to 
histamine are presented in Table 1. The average symptom 
score for 1 week was 11.7 (maximum possible 42) and 
the average P-agonist usage was 32 puffs week- ‘. The 
mean FEV, (% predicted) was 88% and the mean PEF 
diurnal variability was 10.2%. The group geometric mean 
cumulative PC,, histamine (range) was 0.73 mg ml - ’ 
(0.04-8.77 mg ml - ‘). 
Exhaled NO levels were elevated in our study population 
with a mean * SEM of 19.7 & 1.9 ppb compared with values 
recorded in normal subjects of 11.1 f 059 ppb (P<O.OOOl) 
using the same technique (21). 
There was a significant positive correlation between 
PC,, histamine and FEV, (% predicted) (r=0.44; P=O.O26) 
(Fig. 1). Exhaled NO levels correlated negatively with PC,, 
histamine (r=0.51; P=O.OOS) and positively with diurnal 
PEF variability (~0.58; P=O.O02) (Fig. 2). A strong positive 
correlation existed between symptom scores and P-agonist 
use (r=O.85; P<O.O005) (Fig. 3). There was no significant 
correlation between exhaled NO levels and P-agonist use, 
symptom scores or FEV, (% predicted). 
Discussion 
In this study we have demonstrated that steroid-naive 
asthmatics exhale significantly higher levels of NO than 
normal control subjects and that such levels correlate 
negatively with BHR as assessed by the PC,, histamine and 
positively with the PEF diurnal variability expressed as the 
amplitude as a percentage of the mean. 
BHR and variable airflow obstruction are characteristic 
features of asthma and are a consequence of the underlying 
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FIG. 2. Relationship between exhaled NO levels and (a) 
PC,, histamine (Y= - 0.51; P=O.OOS) and (b) PEF diurnal 
variation (r=O.58; P=O.O02). 
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FIG. 3. Relationship between symptom scores and 
P-agonist usage (v=O.85; P<O.O005). 
airway inflammation (l), and both have been used as 
markers for assessment of asthma severity. Studies in 
patients with asthma have shown that bronchial reactivity 
is increased in relation to the clinical severity of the disease 
(24-26) daily requirement for medications to control 
symptoms (24,25,27) and lung function as assessed by PEF 
variability (28) or FEV, (% predicted) (24,26). Our find- 
ing of a significant correlation between PC,, histamine 
and FEV, (% predicted) (Fig. 1) is consistent with these 
observations. Recently, bronchial biopsy studies in asthma 
(16,29,30) have demonstrated a relationship between the 
degree of airway inflammation and bronchial reactivity (29) 
as well as PEF variability (30). Furthermore, following 
treatment with inhaled corticosteroids the reduction in the 
degree of airway inflammation was parallelled by reduction 
in bronchial reactivity and improvement in lung function 
(16). All these observations suggested that bronchial 
reactivity and PEF variability might be useful markers for 
monitoring asthma severity. However, measurement of 
airway hyperresponsiveness can be distressing to the patient 
owing to the induced bronchoconstriction and relatively 
difficult to perform in clinical practice. In addition, 
this measure is influenced by concurrent-bronchodilator 
medication and, even with optimal control of asthma, 
improvements in bronchial reactivity are often modest and 
still remain abnormal. Similarly, although serial measure- 
ments of PEF are easy to perform, the results may not 
reflect the underlying airway inflammation as the results of 
these measurements will also be affected by the use of 
inhaled or oral bronchodilators. An improved indirect 
marker of airway inflammation is thus required that is easy 
to measure and can be applied clinically. NO measures in 
exhaled air potentially fulfil such criteria. NO is generated 
by NOS and enhanced expression of an inducible form 
of this enzyme is evident in the airways in asthma. 
This enzyme is induced by the cytokines (31) such as 
interleukin-lj?, tumour necrosis factor-u and interferon-;). 
All these cytokines have enhanced potential expression in 
asthma together with other pro-inflammatory cytokines 
(3,32-34). NO is thus likely to reflect airway inflammatory 
events indirectly and our identification of elevated levels of 
NO is consistent with this concept and with the results of 
other studies (11-l 3). 
Our findings of a strong association between exhaled NO 
levels and the two characteristic features of asthma, namely 
bronchial hyperreactivity and PEF diurnal variability, 
suggest that measurements of exhaled NO levels in 
asthmatics might be a useful surrogate for these markers 
in monitoring asthma severity which overcomes the 
limitations attached to these markers as the test is easy to 
perform and the results are not affected by bronchodilator 
use (15). Indeed, Kharitonov et al. in a recent report (35) 
have shown that exhaled NO levels are more sensitive 
than either symptom scores or lung function in detecting 
deterioration in asthma control associated with changes in 
the dose of inhaled corticosteroids. Currently, NO analys- 
ers are expensive and not widely available, but in the future 
cheaper and potentially portable machines might become 
available. 
The other observation we have made is the strong 
association between symptom scores and P-agonist usage 
(Fig. 3). The patients were using more than four puffs of a 
b-agonist per day and thus were inadequately treated and 
should be receiving regular inhaled prophylactic therapy 
(34). However, their average weekly symptoms score was 
only 11.7, which gives the impression that the study popu- 
lation have mild disease. The mean FEV, (‘% predicted) of 
88% gives the same impression. The use of p-agonists 
suggests, however. that their disease is not mild (36) and 
suggests that most patients are underestimating their 
symptoms, making symptom scores an unreliable marker 
for monitoring asthma severity and lending further support 
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to the use of a more objective measure such as exhaled NO 
levels in monitoring asthma. 
Finally, although FEV, measurements indirectly reflect 
airway pathology, PEF diurnal variation over 1 week is 
more likely to reflect the underlying airway mucosal 
inflammation than measurement of FEV, at a single time 
point as this will also be influenced by structural airway 
changes unrelated to current inflammatory events. The 
strong association between exhaled NO levels and PEF 
diurnal variability but not with FEV, (% predicted) would 
support this tenure. 
In conclusion, we have demonstrated that asthmatics 
exhale significantly higher levels of NO than normal control 
subjects and that there is a strong association between 
exhaled NO levels and two characteristic features of 
asthma; bronchial hyperreactivity and diurnal PEF vari- 
ation. These findings lend further support to the suggestion 
that measurement of exhaled NO levels is likely to be a 
valuable technique for the monitoring of the current status 
of airway inflammation in asthma and an aid in the 
determination of the current inhaled anti-inflammatory 
therapy requirements. 
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